What's Happening?
Hikma Pharmaceuticals is set to invest $267 million in expanding its manufacturing capabilities across two sites in Ohio. This investment is part of a larger $1 billion expansion plan in the U.S. The company plans to allocate $216 million to enhance its oral
solid dose and nasal inhalation manufacturing operations in Columbus, Ohio, which is expected to create 50 new jobs. Additionally, $51 million will be used to expand injectable manufacturing capabilities at a plant in Bedford, Ohio, creating up to 300 jobs. The Bedford plant, acquired in 2024, is undergoing upgrades to support commercial production, with full operations expected by 2028. This expansion is aimed at supporting a long-term manufacturing contract with a global pharmaceutical company and building a contract manufacturing business.
Why It's Important?
Hikma's investment underscores Ohio's strategic importance in the pharmaceutical manufacturing sector, potentially boosting local employment and economic growth. The expansion aligns with a broader industry trend of relocating drug production to the U.S. amid political pressures. By enhancing its manufacturing capabilities, Hikma aims to meet increasing demand for pharmaceuticals and support contract manufacturing, which could strengthen its market position. The creation of 350 jobs will have a significant impact on the local economy, providing new opportunities for skilled workers in the region.
What's Next?
Pending approval and finalization of economic development incentives, Hikma will proceed with its expansion plans. The company aims to start full commercial production at the Bedford plant by 2028, with machinery expected to arrive soon. As the expansion progresses, Hikma may seek additional partnerships or contracts to further utilize its enhanced manufacturing capabilities. The success of this investment could influence other pharmaceutical companies to consider similar expansions in the U.S., potentially reshaping the domestic manufacturing landscape.
